-
-
-
-
-
-
-
Natera enhances Panorama prenatal test with deep sequencing technology
-
-
-
-
-
-
-
Natera (NTRA) Misses Q1 EPS by 6c; raises guidance
-
-
-
-
-
-
-
Canaccord Reiterates Buy Rating on Natera (NTRA) following Q4
-
-
-
-
-
-
-
Natera's prenatal test selected for plenary presentation at medical meeting
-
-
-
-
-
-
-
Natera's Signatera test improves breast cancer recurrence prediction
-
-
-
-
-
-
-
Morgan Stanley Assumes Natera (NTRA) at Overweight
-
-
-
-
-
-
-
Natera reports blood test shows 22.5% sensitivity for precancerous polyps
-
416,808 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

